Articles by Siegfried Schmitt - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Siegfried Schmitt

Siegfried Schmitt


Siegfried Schmitt, PhD, principal consultant at PAREXEL.

Articles
Automation: A Cure-All?
October 2, 2014

Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses the benefits of automated processes.

Data Integrity
July 2, 2014

Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses how to ensure data integrity.

Key Considerations for Quality-Technical Agreements
May 30, 2014

A drug sponsor?s responsibility does not end when a task is outsourced.

Quality-Technical Agreements
May 2, 2014

Siegfried Schmitt, principal consultant at PAREXEL, discusses the importance of quality-technical agreements.

The Human Factor
February 2, 2014

Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses how human error can be mitigated in pharmaceutical manufacturing.

The State of Drug Manufacturing in India
January 31, 2014

Some recent high-profile cases of quality issues at Indian manufacturers have given reason to examine manufacturers more closely.

Drug Manufacturing Focus: Why India?
December 2, 2013

Siegfried Schmitt, principal consultant at PAREXEL, discusses the state of drug manufacturing in India.

The Role of Analytical Science in Implementing Quality by Design
March 2, 2013

The authors present topics discussed and conclusions that resulted from the PDA QbD workshop.

The Freeze Drying Challenge
April 1, 2012

There are no two completely identical freeze dryer units in operation anywhere.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here